The US Food and Drug Administration on Monday granted accelerated approval for US drugmaker AbbVie’s (NYSE: ABBV) Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy.
Venclexta, which has been developed in cooperation with Swiss pharma giant Roche (ROG: SIX) and its subsidiary Genentech, is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is over-expressed in many patients with CLL.
Venclexta will be available to people in the USA within about one week, said Genentech and AbbVie in their separate press releases. For those who qualify, Genentech and AbbVie plan to offer patient assistance programs for people taking Venclexta.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze